Stay updated on CTX001 in β-Thalassemia: Safety/Efficacy Clinical Trial
Sign up to get notified when there's something new on the CTX001 in β-Thalassemia: Safety/Efficacy Clinical Trial page.

Latest updates to the CTX001 in β-Thalassemia: Safety/Efficacy Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.3.4 updated from v3.3.3; no changes to core study content, eligibility criteria, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check10 days agoChange DetectedPublications section updated: added Improvements in health-related quality of life in patients with transfusion-dependent beta-thalassemia after exagamglogene autotemcel (Blood Advances, 2025, DOI: 10.1182/bloodadvances.2025016702) and removed the earlier ahead-of-print version of the same study. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedThe study record now includes IPD Plan Description and data sharing criteria, and lists new locations (California, Illinois, New York, Pennsylvania, and Tennessee). It also updates the status with Completed/Actual dates and removes outdated sections such as HHS Vulnerability Disclosure and Active, not recruiting.SummaryDifference1%

- Check54 days agoChange DetectedMinor editorial updates to the Publications section clarify that PubMed-sourced publications are auto-filled and may not relate to the study, and update the revision label from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check61 days agoChange DetectedRemoved a site-wide note about government funding status. The study details, eligibility criteria, and outcomes listed on the page remain unchanged.SummaryDifference0.3%

- Check82 days agoChange DetectedMinor layout and formatting updates observed on the page; core study details such as eligibility criteria, primary outcomes, study status, and locations appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to CTX001 in β-Thalassemia: Safety/Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTX001 in β-Thalassemia: Safety/Efficacy Clinical Trial page.